Skip to main content

Table 1 Demographic and MRI features of the MS subjects

From: Saliva soluble HLA as a potential marker of response to interferon-β1a in multiple sclerosis: A preliminary study

Number of MS patients

17 (F/M = 11/6)

Age (Mean ± SD)

29 ± 3 years

MS duration prior to diagnosis

9 ± 2 months

Number of T1-weighted post-contrast enhancing lesions

 

   At least one at month 0

(N = 6)

   At least one at month 6

(N = 0)

Number of relapses during the six months prior to study entry

 

   Two relapses

(N = 2)

   One relapse

(N = 15)